Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tebentafusp + durvalumab + tremelimumab
- Development stage
- Discontinued
- Lead developer
- Immunocore
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
A **combination regimen** of tebentafusp (a gp100×CD3 ImmTAC bispecific T-cell engager), durvalumab (a monoclonal antibody targeting PD-L1), and tremelimumab (a monoclonal antibody targeting CTLA-4), evaluated primarily for advanced or metastatic melanoma and tested in heavily pretreated patients. Tebentafusp redirects T-cells to gp100-positive melanoma cells (HLA-A*02:01-positive), while durvalumab and tremelimumab act as immune checkpoint inhibitors by blocking immune inhibitory pathways (PD-L1/PD-1 and CTLA-4, respectively) to enhance anti-tumor immune responses. Used together, this combination aims to improve immune-mediated tumor cell killing in patients previously treated with or relapsed after anti-PD(L)1 therapies. The safety profile of the triplet is consistent with the established profiles of the individual drugs, with no new safety signals. This combination is not currently an approved therapy but has demonstrated promising clinical activity, including improved tumor shrinkage and overall survival in phase 1b/2 studies for metastatic cutaneous melanoma[1][3][9].
- Brand names
- Imcgp100 + Imfinzi + Imjudo
- Other names
- tebentafusp + durvalumab + tremelimumab
02
Targets
CD3 (T-cell surface glycoprotein CD3)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)CD274 (Programmed cell death protein 1 ligand 1)PMEL (Melanocyte Protein PMEL)
Beyond the preview
Go deeper on tebentafusp + durvalumab + tremelimumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tebentafusp + durvalumab + tremelimumab.